Skip to main content
Brock O'Neil
( out of 186 reviews )

Brock O'Neil, MD

Languages spoken: English, Italian

Clinical Locations

  • Brock O’Neil, MD is an associate professor in the Division of Urology at the University of Utah School of Medicine and the Huntsman Cancer Institute. His clinical practice focuses on the surgical treatment of genitourinary malignancies including prostate, bladder, kidney, adrenal, testicular, penile and urethral cancers. He is an experienced robotic, laparoscopic, endoscopic, and open surgeon. Dr O’Neil completed medical school at the University of Rochester, residency at the University of Utah, and fellowship in Urologic Oncology at Vanderbilt University.

    Board Certification

    American Board of Urology

    Patient Rating

    4.9 /5
    ( out of 186 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 24, 2023
    HUNTSMAN CANCER CENTER

    Honestly, my biggest complaint was waiting 50 minutes after a scheduled appointment. I think it's very disrespectful to leave people hanging when they have taken great effort to do business with you. I am having a hard time getting past the level of disrespect shown to me by his PA. She hung up on me. I didn't curse at her or call her any name, I was merely upset over having to wait almost an hour after a scheduled 07:30 PST appointment.

    August 20, 2023
    HUNTSMAN CANCER CENTER

    Our discussion was brief, to the point, and thorough.

    August 19, 2023
    HUNTSMAN CANCER CENTER

    My impression is that he really does care about his patients and gives them the best possible care.

    August 12, 2023
    HUNTSMAN CANCER CENTER

    Even though the treatment modality we were hoping for was not available for bladder cancer, he took the time to carefully review all records/pathology slides sent to him and affirmed the direction we were going here locally as being the right thing to do. That gave us more peace of mind and confidence in moving forward.

    August 04, 2023
    HUNTSMAN CANCER CENTER

    Its pretty simple. He is a talented surgeon and a nice man. What else matters? Highly recommend!

    August 04, 2023
    HUNTSMAN CANCER CENTER

    Dr ONeil provided clear, information. His consultation with me was very helpful.

    July 21, 2023
    HUNTSMAN CANCER CENTER

    He is very good and honest about all of his findings. We are pleased with everything about him.

    July 07, 2023
    HUNTSMAN CANCER CENTER

    He was very informative which was so great.Thank you

    July 01, 2023
    HUNTSMAN CANCER CENTER

    Very glad I have him for my treatment

  • Brock O’Neil, MD is an associate professor in the Division of Urology at the University of Utah School of Medicine and the Huntsman Cancer Institute. His clinical practice focuses on the surgical treatment of genitourinary malignancies including prostate, bladder, kidney, adrenal, testicular, penile and urethral cancers. He is an experienced robotic, laparoscopic, endoscopic, and open surgeon. Dr O’Neil completed medical school at the University of Rochester, residency at the University of Utah, and fellowship in Urologic Oncology at Vanderbilt University.

    Board Certification and Academic Information

    Academic Departments Surgery -Primary
    Academic Divisions Urology
    Board Certification
    American Board of Urology

    Education history

    Fellowship Urologic Oncology and Health Services Research - Vanderbilt University Fellow
    Urology - University of Utah Resident
    Internship General Surgery - University of Utah Intern
    Doctor of Medicine with Distinction in Research - University of Rochester School of Medicine & Dentistry M.D.
    Undergraduate Exercise Science, Minor in Sociology - Brigham Young University B.S.

    Selected Publications

    Journal Article

    1. Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, Talwar R, Morgans AK, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, ONeil BB, Koyama T, Hoffman KE, Barocas DA (2024). Functional Outcomes After Localized Prostate Cancer Treatment. JAMA, 331(4), 302-317. (Read full article)
    2. Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, ONeil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB (2023). Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. (Read full article)
    3. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Haaland B, Porucznik CA, Gren LH, Sanchez A, Lloyd S, ONeil B, Hashibe M (2023). Mental health outcomes in a population-based cohort of patients with prostate cancer. J Natl Cancer Inst. (Read full article)
    4. Nielsen S, ONeil B, Chang CP, Mark B, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Henry NL, Lloyd S, Hashibe M (2023). Determining the association of rurality and cardiovascular disease among prostate cancer survivors. Urol Oncol, 41(10), 429.e15-429.e23. (Read full article)
    5. Huang D, Chang CE, Newman M, Deshmukh V, Snyder J, Date A, Galvao C, Lloyd S, Henry NL, ONeil B, Hashibe M (2023). Adverse health outcomes among rural prostate cancer survivors: A population-based study. Cancer Epidemiol, 86, 102430. (Read full article)
    6. Lange SM, Vehawn J, Choudry MM, Ambrose JP, Cluff CM, Haaland BA, Paudel N, Chipman J, Hanson HA, ONeil BB (2023). Low-Value Prostate Cancer Screening Among Young Men With Private Insurance. Urol Pract, 101097UPJ0000000000000461. (Read full article)
    7. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Porucznik CA, Gren LH, Sanchez A, Lloyd S, Haaland B, ONeil B, Hashibe M (2023). Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer. JCO Clin Cancer Inform, 7, e2300083. (Read full article)
    8. ONeil B, Dindinger-Hill K, Gill H, Coombs L, Haaland B, Ying J, Nelson RE, McPherson J, Kirchhoff AC, Ulrich CM, Huber J, Beck A, Mooney K (2023). Cost and Utilization Outcomes in Huntsman at Home, a Novel Oncology Hospital at Home Program. J Am Med Dir Assoc. (Read full article)
    9. Harper J, Hunt T, Choudry M, Kapron AL, Cooney KA, Martin C, Ambrose J, ONeil B (2023). Clinician interest in clinical decision support for PSA-based prostate cancer screening. Urol Oncol, 41(3), 145.e17-145.e23. (Read full article)
    10. Tallman JE, Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Hoffman KE, Barocas DA (2022). Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. (Read full article)
    11. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2022). Reply by Authors. J Urol, 208(6), 1239. (Read full article)
    12. Samora NL, Wallis CJD, Huang LC, Tallman JE, Zhao Z, Hoffman K, Morgans A, Cooperberg M, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan S, ONeil B, Paddock LE, Stroup A, Wu XC, Koyama T, Penson DF, Barocas DA (2022). Association between body mass index and localized prostate cancer management and disease-specific quality of life. BJUI Compass, 4(2), 223-233. (Read full article)
    13. Lange SM, Choudry MM, Hunt TC, Ambrose JP, Haaland BA, Lowrance WT, Hanson HA, ONeil BB (2022). Impact of choosing wisely on imaging in men with newly diagnosed prostate cancer. Urol Oncol. (Read full article)
    14. Joyce DD, Wallis CJD, Huang LC, Hoffman KE, Zhao Z, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2022). The Association between Financial Toxicity and Treatment Regret in Men with Localized Prostate Cancer. JNCI Cancer Spectr. (Read full article)
    15. Harper JB, Greenberg SE, Hunt TC, Cooney KA, ONeil BB (2022). Initial outcomes and insights from a novel high-risk prostate cancer screening clinic. Prostate. (Read full article)
    16. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2022). Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study. J Urol, 101097JU0000000000002902. (Read full article)
    17. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, ONeil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson S (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clin Genitourin Cancer, 20(6), e453-e459. (Read full article)
    18. Tallman JE, Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2022). Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate Cancer Prostatic Dis. (Read full article)
    19. Vehawn J, ONeil B (2021). Identifying Top Talent to Improve Prostatectomy Sexual Outcomes: Is the Juice Worth the Squeeze? JAMA Surg, 157(2), 144-145. (Read full article)
    20. Luckenbaugh AN, Wallis CJD, Huang LC, Wittmann D, Klaassen Z, Zhao Z, Koyama T, Laviana AA, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Hoffman KE, Penson DF, Barocas DA (2022). Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes. J Urol, 207, 101097JU0000000000002370. (Read full article)
    21. Slade AD, Cardinal JR, Martin CR, Presson AP, Allen CD, Lowrance WT, Dechet CB, ONeil BB (2021). Feasibility of wearable activity trackers in cystectomy patients to monitor for postoperative complications. Curr Urol, 15(4), 209-213. (Read full article)
    22. Hunt TC, Ambrose JP, Haaland B, Kawamoto K, Dechet CB, Lowrance WT, Hanson HA, ONeil BB (2021). Decision fatigue in low-value prostate cancer screening. Cancer, 127(18), 3343-3353. (Read full article)
    23. Dorff TB, ONeil B, Hoffman KE, Lin DW, Loughlin KR, DallEra M (2021). 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urol Oncol, 39(9), 521-527. (Read full article)
    24. Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, 39(23), 2586-2593. (Read full article)
    25. Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Tallman JE, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2021). Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. Urol Oncol, 40, 56.e1-56.e8. (Read full article)
    26. Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2021). Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer, 127(11), 1912-1925. (Read full article)
    27. Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, ONeil BB, Tward JD (2021). Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO Precis Oncol, 5. (Read full article)
    28. Stone BV, Laviana AA, Luckenbaugh AN, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Joyce DD, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. J Urol, 205(3), 761-768. (Read full article)
    29. Lange SM, Ambrose JP, Flynn MC, Lowrance WT, Hanson HA, ONeil BB (2021). Prostate-specific antigen testing among young men: an opportunity to improve value. Cancer Med, 10(6), 2075-2079. (Read full article)
    30. Reisz PA, Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. J Urol, 204(6), 1236-1241. (Read full article)
    31. Huelster HL, Laviana AA, Joyce DD, Huang LC, Zhao Z, Koyama T, Hoffman KE, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg M, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urol Oncol, 38(12), 930.e23-930.e32. (Read full article)
    32. Klett DE, ONeil B (2020). Transurethral Resection of a Bladder Tumor in Pregnancy: Decidual Reaction Bladder Endometriosis. J Endourol Case Rep, 6(3), 132-134. (Read full article)
    33. Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. Eur Urol, 78(2), 248-255. (Read full article)
    34. Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clin Genitourin Cancer, 18(4), 274-283.e5. (Read full article)
    35. Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, ONeil B, Lowrance W (2020). 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urol Oncol, 38(7), 636.e1-636.e6. (Read full article)
    36. Leiser CL, Taddie M, Hemmert R, Richards Steed R, VanDerslice JA, Henry K, Ambrose J, ONeil B, Smith KR, Hanson HA (2020). Spatial clusters of cancer incidence: analyzing 1940 census data linked to 1966-2017 cancer records. Cancer Causes Control, 31(7), 609-615. (Read full article)
    37. Oswald N, Lin T, Haaland B, Flynn M, Kawamoto K, Cooney KA, Lowrance W, Hanson HA, ONeil B (2020). Factors associated with appropriate and low-value PSA testing. Cancer Epidemiol, 66, 101724. (Read full article)
    38. Leiser CL, Anderson RE, Martin C, Hanson HA, ONeil B (2020). Combining Drive Time and Urologist Density to Understand Access to Urologic Care. Urology, 139, 78-83. (Read full article)
    39. Hanson HA, Leiser CL, ONeil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp NJ (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer Epidemiol Biomarkers Prev, 29(5), 918-926. (Read full article)
    40. Jalali A, Martin C, Nelson RE, Vanneman ME, Martin BI, Cooney KA, Waitzman NJ, ONeil B (2019). Provider Practice Competition and Adoption of Medicare's Oncology Care Model. Med Care, 58(2), 154-160. (Read full article)
    41. Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA (2020). Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA, 323(2), 149-163. (Read full article)
    42. Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2019). Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes? J Urol, 202(6), 1150-1158. (Read full article)
    43. Hanson HA, Martin C, ONeil B, Leiser CL, Mayer EN, Smith KR, Lowrance WT (2019). The Relative Importance of Race Compared to Health Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. J Urol, 202(6), 1209-1216. (Read full article)
    44. Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, ONeil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C (2019). Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol, 37(33), 3090-3098. (Read full article)
    45. Martin C, ONeil B, Lowrance W, Leiser C, Mayer E, Smith K, Hanson H (2019). The Relative Importance of Race Compared to Healthcare and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. J Urol.
    46. Laviana A, Hernandez A, Zhao Z, Huang L, Koyama T, Conwill R, Feurer I, Hoffman K, Goodman M, Hamilton A, Wu X, Paddock L, Stroup A, Cooperberg M, Hashibe M, ONeil B, Penson D, Barocas D (2019). Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes? J Urol.
    47. Martin C, Haaland B, Tward AE, Dechet C, Lowrance W, Stephenson RA, Hanson H, ONeil B (2018). Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making. J Urol, 201(4), 751-758. (Read full article)
    48. Tward JD, Poppe MM, Hitchcock YJ, ONeil B, Albertson DJ, Shrieve DC (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med, 7(12), 6030-6039. (Read full article)
    49. ONeil B, Hoffman KE, Koyama T, Alvarez JR, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Kaplan SH, Hashibe M, Stanford JL, Stroup AM, Paddock LE, Chen V, Wu XC, Resnick MJ, Penson DF, Barocas DA (2017). Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer. Urol Pract, 5(6), 471-479. (Read full article)
    50. ONeil B, Martin C, Kapron A, Flynn M, Kawamoto K, Cooney KA (2018). Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines. Cancer Epidemiol, 56, 112-117. (Read full article)
    51. Martin C, Leiser CL, ONeil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 110(5), 527-533. (Read full article)
    52. ONeil B, Tyson M, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2017). The influence of provider characteristics and market forces on response to financial incentives. Am J Manag Care, 23(11), 662-667. (Read full article)
    53. ONeil BB, Hoffman KE, Tasuki K, et al (2017). Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiotherapy Versus External Beam Radiotherapy of the Mid-1990's for Localized Prostate Cancer. Urol Pract.
    54. Martin C, Leiser CL, ONeil BB, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A population-Based Case-Control Study. J Natl Cancer Inst.
    55. ONeil B, Maughan B (2017). A More Common Massive Retroperitoneal Mass. JAMA Surg, 152(8), 802-803. (Read full article)
    56. ONeil B, Tyson MD, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2017). The Influence of Provider Characteristics and Market Forces on Response to Financial Incentives.
    57. Sohn W, Graves AJ, Tyson MD, ONeil BB, Chang SS, Ni D, Barocas DA, Penson DF, Resnick MJ (2016). An Empiric Evaluation of the Effect of Variation in Intensity of Follow-Up for Surgically Treated Renal Neoplasms: Estimating Value in Survivorship Care. J Urol.
    58. ONeil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 195(2), 321-9. (Read full article)
    59. ONeil BB, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2015). Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. J Natl Cancer Inst, 108(2).
    60. ONeil BB, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, and Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 196.
    61. ONeil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant WO (2014). Climacturia after definitive treatment of prostate cancer. J Urol, 191(1), 159-63. (Read full article)

    Review

    1. Lange S, ONeil B (2021). Increasing the value of PSA through improved implementation. [Review]. Urol Oncol. (Read full article)

    Conference Proceedings

    1. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, ONeil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG (2020). Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol, United States, 38(24), 2798-2811. (Read full article)

    Commentary

    1. Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Kaplan SH, Greenfield S, Luckenbaugh AN, Klaassen Z, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Hoffman KE, Barocas DA (2022). Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA Oncol, 8(1), 50-59. (Read full article)

    Editorial

    1. Hunt TC, ONeil BB (2020). Leveraging Behavioral Economics to Reduce Low-value Prostate Cancer Screening. Eur Urol, 77(4), 400-402. (Read full article)

    Letter

    1. Hanson HA, Martin C, Leiser CL, ONeil B, Smith KR (2018). Response to K. Hemminki et al. [Letter to the editor]. J Natl Cancer Inst, 110(11), 1279. (Read full article)
    2. ONeil B, Lowrance WT, Heilbrun ME (2017). PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumors. [Letter to the editor]. JAMA, 318(16), 1614. (Read full article)

    Abstract

    1. ONeil B, Anderson R, Martin C, Leiser C, Hanson H (2019). A Novel Approach to Identify Disparities in Access to Urologic Care Based Upon Driving TIme [Abstract].
    2. Greenberg S, Tward J, Cooney K, Pappas L, ONeil B (2019). Germline genetic testing in men with prostate cancer: clinical characteristics and testing outcomes in a newly indicated population [Abstract].
    3. Armstrong J, Martin C, ONeil B, Dechet C, Morton K, Lowrance W (2018). Fluciclovine PET CT Detection of Biochemical Recurrent Prostate Cancer at Specific PSA Thresholds After Definitive Treatment [Abstract]. WSAUA.
    4. Jalali A, Nelson R, Vanneman M, Martin C, Martin B, Waitzman N, ONeil BB (06/25/2018). Provider Practice Competition and Adoption of Medicare's Oncology Care Model [Abstract]. AcademyHealth.
    5. Hanson H, Leiser C, Martin C, ONeil BB, Lowrance W, Alter O, Gupta S, Kohlman W, Greenberg W, Smith K, Camp N (04/2018). Redefining the Bladder Cancer Phenotype Using Patterns of Familial Risk [Abstract]. Journal of Urology, 199(4).
    6. Martin C, ONeil BB, Kapron A, Kawamoto K, Lowrance W, Flynn M, Cooney K (04/01/2018). Rate of Discordant PSA Testing Among Varied Guidelines: Identifying Targetable Inefficiencies in Our Health System [Abstract]. Journal of Urology, 199(4).
    7. Martin CM, ONeil BB, Kapron A, Flynn M, Kawamoto K, Lowrance WT, Cooney K (2017). Measuring PSA Screening Quality at the Health System Level: Potental Areas for Improvement [Abstract]. Society of Urologic Oncology.

    Other

    1. Tallman JE, Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Hoffman KE, Barocas DA (2023). Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. England. (Read full article)
    2. Tallman JE, Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2023). Correction to: Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate Cancer Prostatic Dis (26(1), p. 214). England. (Read full article)